The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.
Susan Mary O'Brien
Consultant or Advisory Role - Pharmacyclics
Research Funding - Pharmacyclics
Jacqueline Claudia Barrientos
Research Funding - Pharmacyclics
Ian W. Flinn
No relevant relationships to disclose
Paul M. Barr
No relevant relationships to disclose
Jan Andreas Burger
Consultant or Advisory Role - Pharmacyclics
Tasheda Navarro
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Eric Hedrick
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Jonathan W. Friedberg
No relevant relationships to disclose
Jennifer R. Brown
Consultant or Advisory Role - Avila Therapeutics; Novartis; Pharmacyclics
Research Funding - Celgene; Genzyme